{"nctId":"NCT00828204","briefTitle":"Evaluate the Safe and Effective Use of the AvonexÂ® Single-Use Autoinjector in Multiple Sclerosis Subjects","startDateStruct":{"date":"2009-01"},"conditions":["Multiple Sclerosis"],"count":95,"armGroups":[{"label":"Avonex Single-Use Autoinjector","type":"EXPERIMENTAL","interventionNames":["Device: single-use autoinjector with a prefilled liquid Avonex syringe","Device: Avonex prefilled syringe via manual IM injection","Drug: BG9418 (interferon beta-1a)"]}],"interventions":[{"name":"single-use autoinjector with a prefilled liquid Avonex syringe","otherNames":[]},{"name":"Avonex prefilled syringe via manual IM injection","otherNames":[]},{"name":"BG9418 (interferon beta-1a)","otherNames":["Avonex"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information (PHI) in accordance with national and local subject privacy regulations.\n2. Must be 18 to 65 years old, inclusive, at the time of informed consent.\n3. Must currently be self-administering Avonex Prefilled Syringes to treat MS and must have been self-administering Avonex Prefilled Syringes for the 12 weeks prior to the Screening Visit.\n4. In the investigator's opinion, subjects must be willing and able to self-administer all injections required by the protocol.\n5. Must speak English.\n6. All male subjects and female subjects of child-bearing potential must practice effective contraception during the study.\n\nExclusion Criteria:\n\n1. History of seizure disorder or unexplained blackouts OR history of a seizure within 3 months prior to the Screening Visit.\n2. History of suicidal ideation within 3 months prior to Day 1 or an episode of severe depression within 3 months prior to Day 1. Severe depression is defined as any episode of depression that requires hospitalization, or the initiation of antidepressant therapy, or an increase in the dose of an existing regimen of antidepressant therapy. NOTE: Subjects receiving ongoing antidepressant therapy are not excluded from the study unless the dose has been increased within the 3 months prior to the Screening Visit.\n3. Clinically significant local infection (for example cellulitis, abscess) or systemic infection (pneumonia, septicemia), at the discretion of the Investigator.\n4. Known history of Human Immunodeficiency Virus (HIV).\n5. Known history of, or positive test result for hepatitis C virus (test for hepatitis C virus antibody \\[HCV Ab\\]) or Hepatitis B virus (test for Hepatitis B Surface Antigen \\[HBsAg\\] and/or Hepatitis B Core Antibody \\[HBcAb\\]).","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants in the Main Subset With Overall Success Using the Avonex Single-Use Autoinjector","description":"A trainer/observer documented the participant's ability to self-inject with the Avonex single-use autoinjector and completed an observation form. Overall success in using the device for each participant was defined as no failures occurring in any step (ie, device set-up, self-administration of injection, and capping/disposal of the device) during the participant's use of the single-use Avonex autoinjector.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"89","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants in the Initial Subset Who Were Satisfied With the Avonex Single-Use Autoinjector","description":"Number of participants in the Initial Subset who answered yes to the question \"Were you satisfied with this single-use injector?\" on the Subject Satisfaction Questionnaire.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Participants With No Erythema, Induration, or Tenderness, and Normal Temperature at the Injection Site After Injection With the Avonex Single-use Autoinjector","description":"The clinician/investigator evaluated the injection site for erythema, induration, and tenderness as none, mild, moderate, or severe after the use of the Avonex single-use autoinjector. Temperature at the injection site was evaluated as normal, warm, or hot. Those participants having no erythema, induration, or tenderness, and normal temperature at the injection site after injection are presented.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"65","spread":null},{"groupId":"OG001","value":"95","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90","spread":null},{"groupId":"OG001","value":"79","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Mean Score for Ease of Use Grading Scale","description":"Participants scored the ease of use of the Avonex manual injector (Day 1) and single-use autoinjector (Days 8, 15, 22) using a scale that ranged from 0 (extremely difficult) to 10 (extremely easy).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.1","spread":"2.64"},{"groupId":"OG001","value":"7.4","spread":"2.41"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.9","spread":"1.96"},{"groupId":"OG001","value":"6.8","spread":"3.39"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.7","spread":"2.47"},{"groupId":"OG001","value":"6.7","spread":"3.07"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.3","spread":"1.87"},{"groupId":"OG001","value":"5.9","spread":"3.13"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Participants Who Rated the Avonex Single-use Autoinjector Printed and DVD Training Materials as Very Effective","description":"Participants evaluated how effective the printed and DVD instructions were in educating how to use the Avonex single-use autoinjector. Participants could choose one of the following descriptive answers: not effective at all, somewhat ineffective, neutral, somewhat effective, or very effective.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"93","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Mean Score for Initial Subset on Autoinjector Instructions Grading Scale","description":"Participants in the Initial Subset were asked to answer the question \"How satisfied are you with the presentation of the autoinjector instructions?\" on a rating scale of 0 (extremely dissatisfied) to 10 (extremely satisfied).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.5","spread":"0.71"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Participants Who Indicated No Difficulty With the Injection Procedure of the Manual Injection or the Avonex Single-use Autoinjector","description":"Participants assessed whether they had experienced any difficulty with the procedure in preparing, injecting, removing, and disposing process after each injection with the Avonex single-use autoinjector by answering yes or no to the following question: \"Did you have any difficulty with your injection?\" The percentage of participants answering no to this question for both the manual injection on Day 1 and the autoinjector on Days 8. 15 and 22 are presented.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"89","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Participants Who Indicated a Preference for the Avonex Single-use Autoinjector Over the Manual Avonex Prefilled Syringe","description":"Participants were asked whether they preferred using the Avonex single-use autoinjector over the manual Avonex prefilled syringe. Preference was defined as participants answering yes to the following question: Do you prefer this single-use autoinjector over the manual injection?","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"94","spread":null},{"groupId":"OG001","value":"53","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Mean Pain Score After Injection","description":"Participants scored their pain level after the use of the manual prefilled syringe on Day 1 and the Avonex single-use autoinjector on Days 8, 15, and 22 on a scale ranging from 0 (no pain) to 10 (extremely painful).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":"1.76"},{"groupId":"OG001","value":"2.5","spread":"2.87"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":"1.46"},{"groupId":"OG001","value":"1.9","spread":"2.19"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":"1.64"},{"groupId":"OG001","value":"2.1","spread":"1.95"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":"1.13"},{"groupId":"OG001","value":"2.4","spread":"2.99"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":72},"commonTop":["Injection Site Pain","Injection Site Haematoma","Influenza Like Illness","Injection Site Erythema","Anxiety"]}}}